Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
H1N1 flu pandemic could last years
Written by Compiled from Staff and Wire Reports
Sunday, 11 October 2009 00:24
http://biomedreports.com/articles/most-popular/12663-h1n1-flu-pandemic-could-last-years.html
It could take years for the World Health Organization to downgrade the H1N1 flu from a pandemic to seasonal-like virus, the U.N. agency said.
The WHO moved its six-point pandemic alert level to the top rung in June in response to the spread of the new virus widely known as swine flu, which has killed at least 4,500 people, especially in North America.
WHO spokesman Gregory Hartl said that health warning would stay in place until people can better fend off infection from the H1N1 strain.
"At some point in the future, there would be a recognition of the fact that if it's no longer circulating on a sustainable basis in communities. Then you would lower the pandemic level," he said, while stressing: "There is absolutely no indication yet of that happening."
In previous pandemics, Hartl said, it has taken time for worrisome flu strains to become less contagious. The slowdown generally comes from people having some prior exposure to the virus or gaining protection from a vaccine.
"Eventually a pandemic virus becomes more like a seasonal virus and that normally will take something like two to three years," Hartl said. "Once enough people either have been vaccinated or have contracted the virus, then it becomes more difficult to spread. It starts acting like a seasonal flu."
National health authorities conduct regular monitoring of flu viruses and research on the circulating strains is used by pharmaceutical companies who sell seasonal flu shots, which normally contain a mixture of a few viruses.
Several firms now scrambling to develop and sell H1N1 flu shots and at least one other is working on a possible treatment for those who have already been infected. That could yield these companies billions of dollars in government orders. China began the world's first mass vaccination program in late September and Australia and the United States have also launched campaigns targeting children and health workers first.
Hartl said there was no sign yet that the pandemic strain had mutated into a more dangerous or more mild form than the one first identified in Mexico and the United States.
"So far the virus has remained quite homogenous," he said.
In its latest snapshot of the spreading virus, also released on Friday, the WHO said there has been an unusually early start of flu-like illness in the northern hemisphere this autumn.
Influenza viruses thrive in colder climates and normally pack the biggest punch in winter.
Young people at great risk
H1N1 poses a greater danger of severe illness and death for children and young people than seasonal flu, which is particularly dangerous for the elderly.
Only about 20 percent of U.S. children get vaccinated against seasonal flu in a typical year. Some parents, including many at Dodge Park Elementary, are holding back on H1N1 vaccination because of worries about the newness of the vaccine -- concerns that health officials say are unfounded.
The U.S. Centers for Disease Control and Prevention said on Friday that 76 U.S. children have died from H1N1 since April, with widespread swine flu in 37 states.
Most victims had underlying disease but 20 to 30 percent were healthy before they contracted swine flu.
This death toll compares with 46 to 88 pediatric deaths for entire flu seasons over the past three years, the CDC said.
H1N1 Flu Press Conference (CDC): 09/11/2009
H1N1 flu pandemic could last years
Written by Compiled from Staff and Wire Reports
Sunday, 11 October 2009 00:24
http://biomedreports.com/articles/most-popular/12663-h1n1-flu-pandemic-could-last-years.html
Cardium Announces Planned Release of Data from Matrix Excellarate Phase 2b Clinical Study and Acceptance of Phase 1 / 2 Study for Publication in Wound Repair and Regeneration
On Thursday October 1, 2009, 9:00 am EDT
http://finance.yahoo.com/news/Cardium-Announces-Planned-prnews-1714688369.html?x=0&.v=1
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) announced plans to report on preliminary safety and efficacy data from its Matrix Phase 2b Excellarate clinical study. Based on guidance from Cardium's independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial, Cardium expects to receive the locked unblinded data set and be in position to announce preliminary results on or before October 14, 2009. The Company also plans to hold a webcast to review the clinical data, details of which will be provided with announcement of the Matrix clinical results.
Cardium also announced that positive results from the Phase 1 / 2 clinical study of Excellarate have been accepted for publication in Wound Repair and Regeneration, the peer-reviewed medical journal of the Wound Healing Society. The article, entitled Treatment of Nonhealing Diabetic Foot Ulcers with Platelet Derived Growth Factor Gene-Activated Matrix (GAM501): Results of a Phase 1/2 trial (Mulder, et al) is expected to be published and available online in early October 2009.
About Cardium
Cardium is focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses that have the potential to address significant unmet medical needs and definable pathways to commercialization, partnering and other economic monetizations. Cardium's investment portfolio includes the Tissue Repair Company and Cardium Biologics, medical technology companies primarily focused on the development of innovative therapeutic products for wound healing, bone repair, and cardiovascular indications. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that the Matrix study or other human clinical trials can be conducted and completed in an efficient and successful manner, that Excellarate or our other candidates will prove to be sufficiently safe and effective, that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures, that clinical studies even if successful will lead to product advancement or partnering, that our products or product candidates will not be unfavorably compared to competitive products that may be regarded as safer, more effective, easier to use or less expensive; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will be successful or will effectively enhance our businesses or their market value, that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population, or that third parties on whom we depend will perform as anticipated.
Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.
Copyright 2009 Cardium Therapeutics, Inc. All rights reserved.
Tissue Repair - Company Investor Presentation (May, 2009)
http://www.t-r-co.com/pdfs/TRC_Webcast_051409.pdf
Investor Fact Sheet - Women and Cardiovascular Disease
http://www.cardiumthx.com/flash/pdf/AwareWomenHeartDisease.pdf
Investor Fact Sheet - Tissue Repair Company
http://www.t-r-co.com/pdfs/TRC_FactSheet_May2009.pdf
IBOX updated!
CXM - Recommendations
Outperform (Last Updated: 10 Oct 2009)
http://www.reuters.com/finance/stocks/recommendations?symbol=CXM
Please note market is open on Monday!
Posted by: langlui Date: Friday, October 09, 2009 6:35:08 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42377212
Short Interest (Record Date 2009-OctA)
http://www.shortsqueeze.com/?symbol=srz&submit=Short+Quote%99
Short Interest (Shares Short)
1,270,600
Days To Cover (Short Interest Ratio)
0.6
Short Percent of Float
3.13 %
Short Interest - Prior
1,129,700
Short % Increase / Decrease
12.47 %
Short Interest (Record Date 2009-OctA)
http://www.shortsqueeze.com/?symbol=rz&submit=Short+Quote%99
Short Interest (Shares Short)
9,177,600
Days To Cover (Short Interest Ratio)
6.7
Short Percent of Float
14.58 %
Short Interest - Prior
8,599,300
Short % Increase / Decrease
6.72 %
Short Interest (Record Date 2009-OctA)
http://www.shortsqueeze.com/?symbol=nvax&submit=Short+Quote%99
Short Interest (Shares Short)
11,918,500
Days To Cover (Short Interest Ratio)
1.9
Short Percent of Float
15.49 %
Short Interest - Prior
11,011,200
Short % Increase / Decrease
8.24 %
Short Interest (Record Date 2009-OctA)
http://www.shortsqueeze.com/?symbol=heb&submit=Short+Quote%99
Short Interest (Shares Short)
13,449,800
Days To Cover (Short Interest Ratio)
3.6
Short Percent of Float
10.86 %
Short Interest - Prior
13,224,900
Short % Increase / Decrease
1.70 %
... -
?? wann hat der Ixxx jemals im besten Interesse der Aktionäre gehandelt ?!
wenn es wg. dem verlorenen Geld nicht so traurig wäre, würde ich ==> LOL
GN ax
...OK - my fault
...Contest-"Promotion"
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42373829
COLUMBUS DAY CONTEST @ Party Bash-Board
Posted by: augustafriends Date: Friday, October 02, 2009 7:36:05 PM
In reply to: augustafriends who wrote msg# 58026 Post # of 59076 [Send a link via email]
Party Bash/Columbus Day Contest October 12-16, 2009 / WIN 3 month free Subscription to IHUB
"PLEASE READ RULES BELOW"
Visit and Boardmark the board
http://investorshub.advfn.com/boards/board.aspx?board_id=12753
3 Month Free Subscription to IHUB compliments of IHUB Admin Matt-
Rules: ONE STOCK PICK ENTRY
1.) No OTCBB or Pinkies stocks
2.) Only Stocks between $1.00 - $5.99
3.) Winner Will be determined by highest week increase % on stock. Total weekly % gain entry will be the closing price on 16 October 2009.
4.) Post your pick- No earlier 4:01 PM Friday October 9th and no later than 2400 PST Hours on October 11th, 2009
5.) Title all messages (posts) with "Party Bash Columbus Day Contest Pick"
6.) No one can have the same stock. First post first selection.
CONTEST =======> http://investorshub.advfn.com/boards/board.aspx?board_id=12753
XL Capital Ltd to Announce Third Quarter 2009 Results on Wednesday, October 28, 2009
Date : 10/09/2009 @ 3:03PM
Source : PR Newswire
Stock : (XL)
http://ih.advfn.com/p.php?pid=nmona&cb=1255119542&article=39837849&symbol=NY^XL
"Party Bash Columbus Day Contest Pick" - CXM
Monday, October 12, 2009 Columbus Day
...closed!
http://www.secfile.net/SEC_calendar.htm#Calendar%20of%20SEC%20Holidays
...will work on IBOX at WE
ax
?? you need help with CXM-IBOX ??
...then add me as an assistant!
Examples:
http://investorshub.advfn.com/boards/board.aspx?board_id=7177
http://investorshub.advfn.com/boards/board.aspx?board_id=15297
Skymark Research Initiates Independent Research Coverage On Cardium Therapeutics, Inc.
* Press Release
* Source: Skymark Research
* On 9:00 am EDT, Friday October 9, 2009
http://finance.yahoo.com/news/Skymark-Research-Initiates-pz-115358112.html?x=0&.v=1
Interview with Dr. William Carter, CEO of Hemispherx Biopharma
Written by M.E.Garza
Friday, 09 October 2009 00:00
http://biomedreports.com/articles/most-popular/12587-interview-with-dr-william-carter-ceo-of-hemispherx-biopharma.html
Sunrise Enters Into Agreement to Sell 21-Community Portfolio for $204 Million
Date : 10/09/2009 @ 7:00AM
Source : PR Newswire
Stock : Sunrise Senior Living (SRZ)
http://ih.advfn.com/p.php?pid=nmona&cb=1255087111&article=39829643&symbol=NY^SRZ
Sunrise Expects to Retain Approximately $60 Million in Proceeds
MCLEAN, Va., Oct. 9 /PRNewswire-FirstCall/ -- Sunrise Senior Living, Inc. (NYSE:SRZ) today announced that it has entered into an agreement to sell 21 wholly owned assisted living communities, located in 11 states, to BLC Acquisitions Inc., an affiliate of Brookdale Senior Living Inc. (NYSE:BKD), for $204 million. BLC Acquisitions has placed into escrow an earnest money deposit of $5 million toward the purchase price. The closing date is currently scheduled for November 16, 2009. At the closing of the sale, Sunrise is expected to receive approximately $60 million in proceeds after payment or assumption by BLC Acquisitions of certain mortgage loans, the posting of required escrows, and payment of expenses by Sunrise, but prior to the use of any such funds to repay a portion of the outstanding amounts under Sunrise's bank credit facility. Closing of the transaction is conditioned, among other things, on obtaining the requisite consent of the Company's lenders under its bank credit facility by 5 p.m. on October 19, 2009.
The Company expects to record an impairment charge of approximately $7 million in the third quarter of 2009 to write down five of the 21 communities to fair value. The Company expects to record a gain on the sale of real estate of approximately $50 million upon closing of the transaction.
"This is another important step in our restructuring process and provides us with needed funds to pay down our bank line and with additional working capital," said Mark Ordan, Sunrise's chief executive officer. "We are particularly pleased that our residents and team members in these communities will join a fine and committed operator like Brookdale."
Sunrise was advised on the sale by Goldman, Sachs and Co.
About Sunrise Senior Living
Sunrise Senior Living, a McLean, Va.-based company, employs approximately 40,000 people. As of June 30, 2009, Sunrise operated 415 communities in the United States, Canada, Germany and the United Kingdom, with a combined unit capacity of approximately 42,750 units. Sunrise offers a full range of personalized senior living services, including independent living, assisted living, care for individuals with Alzheimer's and other forms of memory loss, as well as nursing and rehabilitative services. Sunrise's senior living services are delivered by staff trained to encourage the independence, preserve the dignity, enable freedom of choice and protect the privacy of residents. To learn more about Sunrise, please visit http://www.sunriseseniorliving.com/.
Forward-Looking Statements
Certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Sunrise believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, there can be no assurances that these expectations will be realized. Sunrise's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the risk that the Company's sale of the 21-community portfolio is not consummated, changes in the Company's anticipated cash flow and liquidity; the Company's ability to maintain adequate liquidity to operate its business and execute its restructuring; the Company's ability to obtain waivers, cure or reach agreements with respect to defaults under the Company's loan, joint venture and construction agreements; the risk that a group of the Company's creditors, acting together, could force the Company into an involuntary bankruptcy proceeding; the Company's ability to sell its Germany communities and settle the related debt within a reasonable time period, and to negotiate a comprehensive restructuring of the Company's obligations in respect of its Fountains portfolio and certain other of its ventures; the Company's ability to refinance its Bank Credit Facility and other debt due in 2009 and/or raise funds from other sources; the Company's ability to achieve anticipated savings from the Company's cost reduction program; the outcome of the U.S. Securities and Exchange Commission's investigation; the outcome of the IRS audit of the Company's tax returns for the tax years ended December 31, 2005, 2006 and 2007; the Company's ability to continue to recognize income from refinancings and sales of communities by ventures; risk of changes in the Company's critical accounting estimates; risk of further write-downs or impairments of the Company's assets; risk of future obligations to fund guarantees and other support arrangements to some of the Company's ventures, lenders to the ventures or third-party owners; risk of declining occupancies in existing communities or slower than expected leasing of new communities; risk resulting from any international expansion; development and construction risks; availability of financing for development, including construction loans as to which we are in default; risks associated with past or any future acquisitions; compliance with government regulations; risk of new legislation or regulatory developments; business conditions and market factors that could affect occupancy rates at and revenues from the Company's communities and the value of the Company's properties generally; competition and our response to pricing and promotional activities of our competitors; changes in interest rates; unanticipated expenses; the risks of further downturns in general economic conditions including, but not limited to, financial market performance, consumer credit availability, interest rates, inflation, energy prices, unemployment and consumer sentiment about the economy in general; risks associated with the ownership and operation of assisted living and independent living communities; and other risks detailed in the Company's 2008 Annual Report on Form 10-K filed with the SEC, as may be amended or supplemented in the Company's Form 10-Q filings or otherwise. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events.
DATASOURCE: Sunrise Senior Living, Inc.
CONTACT: Meghan Lublin, Corporate and Investor Communications, Sunrise
Senior Living, +1-703-854-0299
Web Site: http://www.sunriseseniorliving.com/
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for FUSILEV® in Advanced Metastatic Colorectal Cancer
09.10.2009 13:02
http://www.finanznachrichten.de/nachrichten-2009-10/15162553-spectrum-pharmaceuticals-receives-complete-response-letter-from-fda-for-fusilev-in-advanced-metastatic-colorectal-cancer-004.htm
Why invest in CEL-SCI Corp (CVM)
Oct 9, 2009 01:43 AM
http://seekingalpha.com/instablog/497084-dimitrije/30995-why-invest-in-cel-sci-corp-cvm
CVM DD -
Why invest in CEL-SCI Corp (CVM)
Oct 9, 2009 01:43 AM
http://seekingalpha.com/instablog/497084-dimitrije/30995-why-invest-in-cel-sci-corp-cvm
!! Adam F. do it again...
http://www.thestreet.com/_yahoo/story/10609175/1/hemispherx-ceo-spills-ampligen-beans-to-stock-cheerleader-biobuzz.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
IMO: HEB is a WINNER!
Study Isolates Virus in Chronic Fatigue Sufferers
By David Morgan
October 8, 2009
http://abcnews.go.com/Technology/WireStory?id=8783360&page=1
HEB ==> http://www.hemispherx.net/content/rnd/cfs.htm
HEB - Clinical Trial http://www.hemispherx.net/content/rnd/clinical_trials_cfs.htm
BIOMED-REPORT
Study Isolates Virus in Chronic Fatigue Sufferers
Written by Staff and Wire Reports
Thursday, 08 October 2009 11:38
http://biomedreports.com/articles/most-popular/12542-study-isolates-virus-in-chronic-fatigue-sufferers.html
Study Isolates Virus in Chronic Fatigue Sufferers
By David Morgan
October 8, 2009
http://abcnews.go.com/Technology/WireStory?id=8783360&page=1
HEB ==> http://www.hemispherx.net/content/rnd/cfs.htm
Special Report on Hemispherx Biopharma coming on Friday
On Friday at BioMedReports, Dr. William A. Carter, CEO of Hemispherx BioPharma, Inc. (AMEX:HEB) is expected to share some important news about the company's pending FDA decision and some new information about the company's Alferon LDO (Low Dose Oral) application.
http://www.biomedreports.com
Posted by: Kiwi99 Date: Thursday, October 08, 2009 3:26:53 PM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=42326082
Purchase of ProLogis European Properties' units completed
http://www.hugingroup.com/pr.asp?pr_id=101632&folder=200910&src=2
Luxembourg - 8 October 2009 - ProLogis European Properties (Euronext: PEPR), one of Europe's largest owners of modern distribution facilities, announced today that the purchase of ?100,000 of PEPR units has been completed. A total of 22,478 PEPR units were purchased at an average price of ?4.4377 per unit. The highest price paid per unit was ?4.447 and the lowest price was ?4.415.
-Ends-
For further information, please contact:
Investor relations
ProLogis European Properties
Jennifer van der Eem
+44 207 518 8708
jvandereem@prologis.com
Media
M:Communications
Ed Orlebar / Charlotte McMullen
+44 20 7920 2323 or 7920 2349
orlebar@mcomgroup.com / mcmullen@mcomgroup.com
About ProLogis European Properties (PEPR)
ProLogis European Properties, or PEPR, is one of the largest pan-European owners of high quality distribution and logistics facilities. PEPR was established in 1999 as a closed-end, real estate investment fund, externally managed by a subsidiary of ProLogis (NYSE: PLD), a leading global provider of industrial distribution facilities. In September 2006, PEPR was listed on Euronext Amsterdam.
As at 30 June 2009, PEPR has a portfolio of 232 buildings, covering 4.9 million square metres in 11 European countries, with a market value of ?3.0 billion. The portfolio has an occupancy level of 96.9% and an average of 3.6 years to the next lease break or 5.8 years to lease expiry.
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Phase 2 Study of KRX-0401 (Perifosine) in Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Open
Date : 10/08/2009 @ 8:30AM
Source : PR Newswire
Stock : Keryx Biopharmaceuticals (MM) (KERX)
http://ih.advfn.com/p.php?pid=nmona&cb=1255007076&article=39813020&symbol=N^KERX
ProLogis Leases 341,000 Square Feet of Its Development Portfolio in France
Date : 10/08/2009 @ 7:00AM
Source : PR Newswire
http://ih.advfn.com/p.php?pid=nmona&cb=1255000209&article=39811183&symbol=NY^PLD
ProLogis Signs Agreements with Three Customers, Including Geodis and Transport Breger -
PARIS, Oct. 8 /PRNewswire-FirstCall/ -- ProLogis (NYSE:PLD), a leading global provider of distribution facilities, announced today it has leased a total of 341,000 square feet (31,700 square meters) during the third quarter to three customers in France.
"Our customers throughout southern Europe continue to seek large, modern and efficient distribution facilities to improve the effectiveness of their distribution networks," said Ranald Hahn, managing director for ProLogis in southern Europe. "ProLogis is well positioned to capture new business because we have available, high-quality distribution space throughout the region, and we are highly focused on our customers' individual needs. We are pleased to sign new lease agreements with three customers."
Recent activity included transactions in ProLogis' development portfolio with:
-- Geodis, a third-party logistics and international transport provider and subsidiary of SNCF (French Railway), which has signed a lease agreement for 136,000 square feet (12,600 square meters) of newly developed distribution space at ProLogis Park les Portes de Vemars. The distribution facility is located approximately 18 miles (30 kilometers) north of Paris with direct access to the A1 motorway. This is the 20th lease between ProLogis and Geodis, which now occupies approximately 3.3 million square feet (310,700 square meters) of ProLogis distribution space throughout Europe.
"We have consistently turned to ProLogis when the need arises for modern, well-located distribution space," said Claude Coperet, operational director for Geodis in France. "Geodis is proud to offer its customers comprehensive distribution services, and locating at this facility will enable us to continue to provide that added business value."
-- Transport Breger, a third-party logistics provider based in Paris, which has signed a lease agreement for 67,000 square feet (6,200 square meters) of newly developed distribution space at ProLogis Park Rennes. The facility is positioned along the N157 national road within Zone d'Activites du Haut Montigne, a special business zone located approximately 22 miles (36 kilometers) east of the city of Rennes.
-- A leading manufacturer and retailer, which has signed a lease agreement for 139,000 square feet (12,900 square meters) at ProLogis Park Clesud, one of ProLogis' largest distribution parks in southern France totaling 2.4 million square feet (224,000 square meters) across nine buildings. The distribution park enables rapid access to multiple freeways, including the A54, A9, A7 and A8, and is one of only a few in the region able to accept train freight.
The company is an existing ProLogis customer and now occupies approximately 770,000 square feet (71,500 square meters) of ProLogis distribution space in France and the United States.
ProLogis' portfolio of properties in France comprises more than 25 million square feet (2.34 million square meters) of space owned, managed or under development as of June 30, 2009.
About ProLogis
ProLogis is a leading global provider of distribution facilities, with more than 475 million square feet of industrial space (44 million square meters) in markets across North America, Europe and Asia. The company leases its industrial facilities to more than 4,500 customers, including manufacturers, retailers, transportation companies, third-party logistics providers and other enterprises with large-scale distribution needs. For additional information about the company, go to http://www.prologis.com/.
DATASOURCE: ProLogis
CONTACT: Media, Mo Sheahan of ProLogis, +1-303-567-5434,
, or Suzanne Dawson of Linden Alschuler & Kaplan, Inc.,
+1-212-329-1420, ; or Investors, Melissa Marsden of ProLogis,
+1-303-567-5622,
Web Site: http://www.prologis.com/
First H1N1-death in Germany proven
Erster H1N1-Todesfall in Deutschland nachgewiesen
http://magazine.web.de/de/themen/gesundheit/krankheiten/9076198-Erster-H1N1-Todesfall-in-Deutschland-nachgewiesen.html
Securities Registration Statement (simplified form) (S-3/A)
Date : 10/06/2009 @ 1:13PM
Source : Edgar (US Regulatory)
http://ih.advfn.com/p.php?pid=nmona&cb=1254994534&article=39781112&symbol=N^AGEN
...
Table of Contents
Explanatory Note
On August 12, 2009, we filed a Form S-1 registration statement (File No. 333-161277), as amended on August 21, 2009 (the “Registration Statement”), to allow the selling stockholder named in the prospectus contained therein or its pledgees, donees, transferees, or other successors in interest (the “Selling Stockholder”), to sell, from time to time, up to 5,000,000 shares of our common stock, which the Selling Stockholder had acquired in a private placement in the United States, and up to 4,673,900 shares of our common stock issuable upon the exercise of certain warrants that it holds. As of October 1, 2009, we have become eligible to register the shares described above on Form S-3. Accordingly, we hereby amend the Registration Statement by filing this Pre-Effective Amendment No. 1, which relates to the registration of 9,673,900 shares of our common stock, $0.01 par value per share, being registered for resale by the Selling Stockholder.
WORLD VACCINE CONGRESS 2009
Congress Day 3: Thursday 8 October 2009
http://www.terrapinn.com/2009/wvcl/programme.stm
11.40
How outsourcing can enhance and speed up development towards licensure of vaccines
Dr Hanna Nohynek, Senior Vaccine Consultant,
Encorium
12.10
Panel session: how can you align strategies with regulation to avoid barriers to vaccine development?
Ms Mary Allin, Senior Director, Regulatory Affairs,
Wyeth Research
Stephen Cook, Vice President, Head of Worldwide Vaccine Registration Management,
GlaxoSmithKline Biologicals
Dr Hanna Nohynek, Senior Vaccine Consultant,
Encorium
ProLogis European Properties announces the purchase of units to remunerate non-executive directors
http://www.hugingroup.com/pr.asp?pr_id=101570&folder=200910&src=2
Luxembourg - 8 October 2009 - ProLogis European Properties (Euronext: PEPR), one of Europe's largest owners of modern distribution facilities, announced that it expects to purchase ?100,000 of PEPR units over today's trading day. These units will be paid to PEPR's non-executive directors as part of their annual remuneration package.
-Ends-
For further information, please contact:
Investor relations
ProLogis European Properties
Jennifer van der Eem
+44 207 518 8708
jvandereem@prologis.com